Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Sanderson

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βJonathan D Silk, Rachel J M Abbott, Katherine J Adams, et al.
Molecular Therapy. Methods & Clinical Development|June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patientsTianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Molecular Cancer Therapeutics|February 7, 2020
Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor SurveillanceMarco H Hofmann, Rajeswaran Mani, Harald Engelhardt, et al.
Frontiers in Oncology|April 4, 2022
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial TumorsDavid S Hong, Marcus O Butler, Russell K Pachynski, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 24, 2023
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8αVictoria E Anderson, Sara S Brilha, Anika M Weber, et al.
Journal for Immunotherapy of Cancer|January 28, 2022
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10<sup>+</sup> advanced non-small cell lung cancerGeorge R Blumenschein, Siddhartha Devarakonda, Melissa Johnson, et al.
Plos One|October 16, 2018
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) moleculesJane Harper, Katherine J Adams, Giovanna Bossi, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 2, 2021
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-βJonathan D Silk, Rachel J M Abbott, Katherine J Adams, et al.
Molecular Therapy. Methods & Clinical Development|June 14, 2024
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patientsTianjiao Wang, Jean-Marc Navenot, Stavros Rafail, et al.
Cancer Discovery|August 21, 2020
BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK InhibitionMarco H Hofmann, Michael Gmachl, Juergen Ramharter, et al.
Nature Medicine|January 9, 2023
Autologous T cell therapy for MAGE-A4<sup>+</sup> solid cancers in HLA-A*02<sup>+</sup> patients: a phase 1 trialDavid S Hong, Brian A Van Tine, Swethajit Biswas, et al.
Pageof 17